Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]-RPC1063 Excretion Balance Study
NCT02994381Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ozanimod in multiple sclerosis (MS) and ulcerative colitis (UC), sponsored by Celgene Corporation. Primary endpoints: Percentage of elimination of [14C]-RPC1063 up to 4 weeks and Pharmacokinetic- amount of drug excreted up to 4 weeks. Started Oct 2016; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02994381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02994381.